TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $618,221.66 in Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) Director Edward M. Basile sold 7,157 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the sale, the director now owns 8,350 shares of the company’s stock, valued at approximately $721,273. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

TransMedics Group Trading Down 0.6 %

NASDAQ:TMDX opened at $88.66 on Friday. The company has a quick ratio of 10.13, a current ratio of 10.93 and a debt-to-equity ratio of 4.00. The business’s 50 day moving average is $80.76 and its two-hundred day moving average is $67.38. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $99.63. The company has a market cap of $2.89 billion, a PE ratio of -80.60 and a beta of 2.05.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TMDX shares. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $67.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, November 7th. Morgan Stanley raised their price objective on TransMedics Group from $54.00 to $75.00 and gave the company an “equal weight” rating in a research note on Monday, December 4th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $83.33.

Get Our Latest Analysis on TransMedics Group

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. US Bancorp DE lifted its holdings in TransMedics Group by 70.4% during the 4th quarter. US Bancorp DE now owns 5,608 shares of the company’s stock worth $443,000 after buying an additional 2,317 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in shares of TransMedics Group by 7.1% in the 4th quarter. D.A. Davidson & CO. now owns 9,220 shares of the company’s stock worth $728,000 after purchasing an additional 608 shares during the last quarter. UBS Group AG lifted its holdings in shares of TransMedics Group by 68.1% in the 4th quarter. UBS Group AG now owns 40,263 shares of the company’s stock worth $3,178,000 after purchasing an additional 16,309 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of TransMedics Group in the 4th quarter worth approximately $889,000. Finally, Level Four Advisory Services LLC bought a new stake in shares of TransMedics Group in the 4th quarter worth approximately $471,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Read More

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.